Wendy Sergeant, NP
Psychiatric/Mental Health · North Brookfield, MANPI 1871687459
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $6,175 of the $6,544 with a category attached, or 94.4%. AbbVie accounts for 96.2% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2021 at $6,487 and has fallen 99.8% since, to $15 in 2023. Among psychiatric/mental health clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 27 payments — averaging $242.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$6K
- Nestle Healthcare Nutrition Inc.$64
- Sunovion Pharmaceuticals Inc.$42
- Lilly USA, LLC$20
- GSK$17
- Boehringer Ingelheim$17
- plus $88 from 6 others
What the payments were for
- Speaking & faculty fees$6,17594%
- Food & beverage$3475%
- Education$220%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 12 | $6,297 |
| Nestle Healthcare Nutrition Inc. | 3 | $64 |
| Sunovion Pharmaceuticals Inc. | 3 | $42 |
| Lilly USA, LLC | 1 | $20 |
| GSK | 1 | $17 |
| Boehringer Ingelheim | 1 | $17 |
| Johnson & Johnson | 1 | $16 |
| AstraZeneca | 1 | $15 |
| Alkermes, Inc. | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Novo Nordisk | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$6,175
How this compares
$6,544 in reported general payments places this provider in the 95th percentile of 1,284 psychiatric/mental health providers in Massachusetts.
See all psychiatric/mental health providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 122 | $378,081 |
| AustedoDeutetrabenazine | 35 | $210,608 |
| VraylarCariprazine Hcl | 74 | $44,117 |
| NuedextaDextromethorphan Hbr/Quinidine | 23 | $35,117 |
| CaplytaLumateperone Tosylate | 20 | $26,443 |
| VivitrolNaltrexone Microspheres | 12 | $20,064 |
| TrintellixVortioxetine Hydrobromide | 60 | $12,731 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 57 | $8,487 |
| Clozapine | 109 | $8,078 |
| Lamotrigine ErLamotrigine | 33 | $5,176 |
| VyvanseLisdexamfetamine Dimesylate | 13 | $3,727 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 44 | $3,553 |
| Ziprasidone Hcl | 44 | $2,693 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 50 | $2,664 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 24 | $2,217 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $16 | $378,081122 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $14 | $210,60835 claims |
| AbbVieVraylar | $6,297 | $44,11774 claims |
| Alkermes, Inc.Vivitrol | $15 | $20,06412 claims |
| Lilly USA, LLCOlanzapine | $20 | $84372 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,284 psychiatric/mental health providers in Massachusetts.
Other psychiatric/mental health in North Brookfield
- Brianne LienkampMarion$121K
- Ashley BakerQuincy$54K
- Brian BanksPembroke$47K
- Anne-Margaret BotelhoMattapoisett$46K
- Matthew PeculisWalpole$41K
- Sherrie UrenaWorcester$21K
- Irina DauphineeHanover$18K
- Schree PettigrewNew Bedford$18K
- Sherryl RosenLynn$16K
- Kevin NardoneWorcester$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.